MarketBeat
16 Oct 2026, 05:02 UTC · 5h ago
Impact · against what's priced in
enGene provides positive clinical and preclinical catalysts for its surfactant-enhanced therapy, including a safety clearance for a larger cohort and a 2027 data timeline. The upcoming Q4 durability update for the pivotal cohort will be the primary near-term driver for the stock's valuation.
No priced-in read yet
What the story claims
5 claims · scored −1 bearish … +1 bullish · 4 new · 1 priced in
The clinical safety run-in for the surfactant cohort was completed with no dose-limiting toxicities observed.
Newannounced during company webinar on Oct 16
So whatPositive safety clearance allows the company to move into the full cohort of up to 80 patients.
More positive than 81% of claims this week
enGene expects to report a six-month complete response update for approximately 20 patients from the surfactant cohort in mid-2027.
Continue reading
5 related stories
The completion of the surfactant safety run-in without dose-limiting toxicities and the establishment of a mid-2027 catalyst for 20 patients provide new tangible milestones. Additionally, the Q4 durability update will validate if the 54% CR rate is sustainable.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Newannounced during company webinar on Oct 16
So whatThis creates a long-term binary catalyst for FY2027 that likely exceeds the current cash runway.
More positive than 68% of claims this week
The company expects to provide an updated pivotal-cohort data release in the fourth quarter, including an estimate of 12-month durability.
Newannounced during company webinar on Oct 16
So whatThis near-term Q4 catalyst will determine if the 54% CR rate is sustainable enough to support the BLA submission.
More positive than 56% of claims this week
In non-human primates, a polidocanol rinse followed by detalimogene produced approximately ninefold higher mean human IL-12 expression than detalimogene alone.
Newannounced during company webinar on Oct 16
More positive than 56% of claims this week
The LEGEND pivotal cohort showed a 54% complete response rate at any time with a median follow-up of 5.5 months.
Priced inreferenced as May interim update
More positive than 47% of claims this week
Which stocks this story touches
More positive than 79% of ticker scores this week
The company reported positive preclinical findings for its surfactant rinse and a 54% complete response rate in its pivotal cohort.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
21h ago
—
ENGN hasn't traded since this ran. Last close $1.71 (Oct 15); the reaction starts at the next open.
ENGN chart →
